Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 2,409 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Invasive Procedure Clear all

Conditions: Lumbar Spinal Stenosis
Interventions: Interlaminar Decompression; Procedure
Lead sponsor: Vertos Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 13
States / cities: Jonesboro, Arkansas • Los Angeles, California • Napa, California + 9 more

Conditions: Coronary Artery Disease
Interventions: PB127 for Injectable Suspension; Drug
Lead sponsor: Point Biomedical; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 40
States / cities: Tucson, Arizona • Burlingame, California • Long Beach, California + 33 more

Conditions: Urothelial Carcinoma Bladder, Bladder Cancer
Interventions: Gemcitabine, Docetaxel; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Blood Loss
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Osteoarthritis
Interventions: Mini Incision Approach, 2 Incision Approach; Procedure
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Breast Cancer, Metastatic Invasive Lobular Breast Cancer
Interventions: 18F-FAPI-74, 18F-FDG, PET/CT; Drug · Procedure
Lead sponsor: Randy Yeh; Other
Eligibility: 18 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Opioid-use Disorder
Interventions: Active repetitive transcranial magnetic stimulation (rTMS), Sham repetitive transcranial magnetic stimulation (rTMS); Device
Lead sponsor: Rutgers University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Bladder Cancer
Interventions: aminophylline; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 40 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Minimally Invasive Surgical Procedures, Surgical Procedures, Operative
Interventions: N/A observational registry; Other
Lead sponsor: Medtronic; Industry
Eligibility: Not listed
Enrollment: 430 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 14
States / cities: Los Angeles, California • Denver, Colorado • Washington D.C., District of Columbia + 10 more

Conditions: Wrinkle
Interventions: BTL-785-7; Device
Lead sponsor: BTL Industries Ltd.; Industry
Eligibility: 21 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Beverly Hills, California • Birmingham, Michigan

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Early-Stage Breast Carcinoma, Invasive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions: Anastrozole, Letrozole; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Bladder Cancer
Interventions: induction cisplatin, induction 5-fluorouracil, induction gemcitabine, Induction BID radiation therapy, Induction QD radiation therapy, Consolidation BID radiation therapy, Consolidation QD radiation therapy, consolidation gemcitabine, consolidation 5-fluorouracil, consolidation cisplatin, radical cystectomy, Post-Induction Chemoradiotherapy Endoscopic Response Evaluation, adjuvant gemcitabine, adjuvant cisplatin; Drug · Radiation · Procedure
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years to 120 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2022
U.S. locations: 10
States / cities: Atlanta, Georgia • Boise, Idaho • Springfield, Illinois + 5 more

Conditions: Esophageal Carcinoma
Interventions: Non-Interventional Study; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Bladder Cancer
Interventions: Not listed
Lead sponsor: David Latini; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Obesity, Type 2 Diabetes, Metabolic Syndrome
Interventions: Not listed
Lead sponsor: Joslin Diabetes Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Myeloma
Interventions: MRD Assessment; Other
Lead sponsor: Rajshekhar Chakraborty, MD; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Distal Urethral Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Proximal Urethral Cancer, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Regional Transitional Cell Cancer of the Renal Pelvis and Ureter, Stage III Bladder Cancer, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder, Urethral Cancer Associated With Invasive Bladder Cancer
Interventions: ixabepilone; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Heart Failure，Congestive
Interventions: Non-invasive central venous pressure; Device
Lead sponsor: Nihon Kohden; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Mountain View, California

Conditions: Multiple Sclerosis, Relapsing-remitting Multiple Sclerosis (RRMS)
Interventions: High Definition transcranial Direct Current Stimulation, Sham High Definition transcranial Direct Current Stimulation; Device
Lead sponsor: The University of Texas at Dallas; Other
Eligibility: 18 Years to 64 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Richardson, Texas

Conditions: Blood Pressure
Interventions: Caretaker; Device
Lead sponsor: Cooper Norcross Health; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Camden, New Jersey

Conditions: Stroke
Interventions: Thigh Cuff; Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 50 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Urea Cycle Disorder
Interventions: Diagnostic Ultrasound; Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 5 Years to 60 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prader-Willi Syndrome
Interventions: tVNS, intermittent stimulation, tVNS, continuous stimulation; Device
Lead sponsor: Foundation for Prader-Willi Research; Other
Eligibility: 10 Years to 40 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 18
States / cities: Palo Alto, California • San Diego, California • Aurora, Colorado + 14 more

Conditions: Hypertension, Aortic Stenosis, Calcific, Quality of Life, Heart Failure With Preserved Ejection Fraction
Interventions: Eplerenone; Drug
Lead sponsor: North Florida Foundation for Research and Education; Other
Eligibility: 55 Years to 100 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Gainesville, Florida

Search by objective public record fields.

MiDAS I (Mild® Decompression Alternative to Open Surgery): Vertos Mild Patient Evaluation Study

Safety and Efficacy Study of PB127 Ultrasound Contrast Agent for Diagnosis of Coronary Artery Disease

Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer

Comparative Accuracy of Three Versions of Non-Invasive Hemoglobin Monitoring

Study Comparing Mini-Incision Versus 2-Incision Approach for Total Hip Replacement

Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET

Using Combined EEG and Non-invasive Brain Stimulation to Examine and Improve Reward Functioning in Opioid Use Disorder

Study of BCG + Aminophylline Toxicity When Used in the Treatment of Bladder Cancer

Medtronic Signia SDR Product Surveillance Registry

Evaluation of Safety and Efficacy of the BTL-785F Device for Non-invasive Facial Remodeling

Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer

Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer That Was Removed by Surgery

18F-FSPG PET/CT as a Non-Invasive Imaging Biomarker for Treatment Response to Chemoradiation in Esophageal Cancer

Quality of Life and Symptom Management in Patients With Bladder Cancer

Evaluation of Intra-Abdominal Fat in Patients With Type 2 Diabetes Using a Non-Invasive Method

Non-invasive MRD Assessment in Multiple Myeloma

Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer

Comparison of Non-invasive Vs. Invasive Hemodynamic Measurements

Non-invasive Brain Stimulation to Improve Memory in Multiple Sclerosis

Caretaker vs. Blood Pressure Monitoring With Invasive Arterial Pressure Monitoring in Patients With Septic Shock

Non-invasive Measurement of Cerebral Dynamic Autoregulation

Chronic Liver Disease in Urea Cycle Disorders

A Clinical Evaluation of Non-Invasive Vagus Nerve Stimulation for Temper Outbursts in People With PWS

Pressure Assessment to Improve Outcomes After TAVR: a Registry